Home › Trials › NCT06075953

Evaluating active surveillance and hormonal therapy for early-stage breast cancer

DCIS: RECAST Trial -Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Breast Cancer Prevention Pilot Study

Phase 2 Interventional QuantumLeap Healthcare Collaborative · NCT06075953

This study is testing if a combination of careful monitoring and hormonal treatment can help women with early-stage breast cancer avoid surgery while keeping an eye on their condition.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment400 (estimated)
Ages18 Years and up
SexFemale
SponsorQuantumLeap Healthcare Collaborative Academic / other
Drugs / interventionsradiation
Locations27 sites (Berkeley, California and 26 other locations)
Trial IDNCT06075953 on ClinicalTrials.gov

What this trial studies

This trial aims to assess the effectiveness of active surveillance combined with hormonal therapy in patients diagnosed with ductal carcinoma in situ (DCIS), an early form of breast cancer. Participants will be randomized to receive either investigational hormonal treatments or standard hormonal therapy, with evaluations conducted through MRI at three and six months. The study seeks to determine if these approaches can reduce the need for surgical intervention while monitoring disease progression. Additionally, participants will provide blood and saliva samples for immune status and genetic testing.

Who should consider this trial

Good fit: Ideal candidates include females aged 18 and older with a previous diagnosis of hormone receptor-positive DCIS.

Not a fit: Patients with invasive carcinoma or those currently undergoing other treatments for DCIS may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could offer a less invasive management option for patients with DCIS, potentially avoiding unnecessary surgeries.

How similar studies have performed: While there have been studies on active surveillance for breast cancer, this specific combination of hormonal therapy and active surveillance in DCIS is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

A. Female, at least 18 years old

B. Previous diagnosis of HR+ DCIS (at least 50% ER or PR; biopsy will have been performed previously at diagnosis) with or without microinvasion

* Patients with a diagnosis of hormone positive DCIS who have undergone surgery with positive margins that have not been re-excised are candidates to enroll in the trial.

C. Patients who have previously received endocrine therapy should have a washout period of at minimum 4-6 weeks prior to the screening MRI on the RECAST-DCIS trial

D. Bilateral mammogram performed within up to 6 months (180 days) of the start of trial treatment may be used for screening evaluation. If a bilateral mammogram has been performed within 1 year (12 months) of the start of trial treatment, then a diagnostic unilateral mammogram within 6 months (180 days) of the start of trial treatment will be acceptable for screening evaluation.

E. MRI performed on an I SPY (RECAST) approved scanner within 2 months (60 days) of the start of trial treatment for lesion evaluation may be used for screening evaluation.

F. CBC w/ diff, CMP, and Lipid Panel within normal limits within a year of the start of trial treatment. Abnormal labs to be repeated within 60 days prior to the start of trial treatment. Patients will be considered eligible for screening labs that are abnormal or out-of-range if the investigator has deemed the lab results not-clinically significant

G. Negative urine or serum pregnancy test within 1 month of the start of trial treatment

H. Controlled HIV positive patients are allowed as long as their current medication does not contraindicate the study's investigational agent

I. Willingness and ability to provide tumor samples for research

Exclusion Criteria:

A. Pregnant or actively breastfeeding women

B. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history

C. Invasive carcinoma or identification of a mass on MRI that is subsequently biopsied and found to be invasive cancer

D. Co-enrollment in clinical trials of pharmacologic agents requiring an IND

E. Ongoing treatment for DCIS other than what is specified in this protocol

F. Uncontrolled intercurrent illness, including psychiatric conditions, that would limit compliance with study requirements

G. Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of investigational agent and/or tamoxifen. Active inflammatory bowel disease or chronic diarrhea, known active hepatitis A/B/C\*, hepatic cirrhosis, short bowel syndrome, or any upper gastrointestinal surgery including gastric resection or banding procedures

\*Active hepatitis, defined as: A (positive HA antigen or positive IgM); B (either positive HBs antigen or positive hepatitis B viral DNA test above the lower limit of detection of the assay); C (positive hepatitis C antibody result, and quantitative hepatitis C (HCV) ribonucleic acid (RNA) results greater than the lower limits of detection of the assay)

H. Participants who are unable to swallow normally or unable to take tablets and capsules. Predictable poor compliance with oral treatment

Where this trial is running

Berkeley, California and 26 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Ductal Carcinoma in Situactive surveillancehormone therapyendocrine therapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.